Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, WA, 99202, USA.
Novartis Institutes for BioMedical Research, Inc, Cambridge, MA, USA.
Pharm Res. 2024 Aug;41(8):1621-1630. doi: 10.1007/s11095-024-03750-x. Epub 2024 Aug 6.
Predicting the quantitative fraction of glucuronidation (f) by individual UDP-glucuronosyltransferase enzymes (UGTs) is challenging due to the lack of selective inhibitors and inconsistent activity of recombinant UGT systems (rUGTs). Our study compares the relative expression versus activity factors (REF versus RAF) to predict f based on rUGT data to human liver and intestinal microsomes (HLM and HIM).
REF scalars were derived from a previous in-house proteomics study for eleven UGT enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17), whereas RAF was calculated by measuring activities in rUGTs to microsomes of selective UGT probe substrates. Protein-normalized activity factor (pnAF) values were generated after correcting activity of individual UGTs to their corresponding protein abundance. The utility of REF and RAF in predicting f was assessed for three UGT substrates-diclofenac, vorinostat, and raltegravir.
The REF values ranged from 0.02 to 1.75, RAF based on activity obtained in rUGTs to HLM/HIM were from 0.1 to 274. pnAF values were ~ 5 to 80-fold, except for UGT2B4 and UGT2B15, where pnAF was ~ 180 and > 1000, respectively. The results revealed confounding effect of differential specific activities (per pmol) of rUGTs in f prediction.
The data suggest that the activity of UGT enzymes was significantly lower when compared to their activity in microsomes at the same absolute protein amount (pmol). Collectively, results of this study demonstrate poor and variable specific activity of different rUGTs (per pmol protein), as determined by pnAF values, which should be considered in f scaling.
由于缺乏选择性抑制剂以及重组 UGT 系统(rUGTs)的活性不一致,预测个体 UDP-葡糖醛酸基转移酶(UGTs)的葡糖醛酸化定量分数(f)具有挑战性。我们的研究比较了相对表达与活性因子(REF 与 RAF),以根据 rUGT 数据预测人肝和肠微粒体(HLM 和 HIM)中的 f。
11 种 UGT 酶(UGT1A1、UGT1A3、UGT1A4、UGT1A6、UGT1A9、UGT1A10、UGT2B4、UGT2B7、UGT2B10、UGT2B15 和 UGT2B17)的 REF 标度源自之前的内部蛋白质组学研究,而 RAF 则通过测量 rUGTs 对选择性 UGT 探针底物的微粒体的活性来计算。在将个体 UGT 的活性校正至其相应的蛋白质丰度后,生成蛋白归一化活性因子(pnAF)值。评估了 REF 和 RAF 在预测三种 UGT 底物(双氯芬酸、伏立诺他和雷特格韦)的 f 中的作用。
REF 值范围为 0.02 至 1.75,基于 rUGTs 在 HLM/HIM 中的活性获得的 RAF 值为 0.1 至 274。pnAF 值为 5 至 80 倍,UGT2B4 和 UGT2B15 除外,其 pnAF 值分别约为 180 和>1000。结果表明,rUGTs 之间的差异特异性活性(每 pmol)对 f 预测存在混杂效应。
数据表明,与在相同绝对蛋白质量(pmol)下的微粒体中的活性相比,UGT 酶的活性显著降低。总的来说,这项研究的结果表明,不同 rUGTs(每 pmol 蛋白质)的特异性活性(每 pmol)差异很大且不稳定,这应在 f 缩放中加以考虑。